These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 118069)

  • 21. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
    Trier H; Rønne T
    Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
    Kremer JR; Schneider F; Muller CP
    Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rubella eradication: the countdown begins.
    Irons B
    West Indian Med J; 1998 Sep; 47(3):75-6. PubMed ID: 9861854
    [No Abstract]   [Full Text] [Related]  

  • 24. Measles, measles vaccination, and Crohn's disease. Crohn's disease has not increased in Finland.
    Pebody RG; Paunio M; Ruutu P
    BMJ; 1998 Jun; 316(7146):1745-6. PubMed ID: 9652932
    [No Abstract]   [Full Text] [Related]  

  • 25. [Evaluation of a trivalent combined vaccine against measles, parotiditis and rubella].
    Randall AG; Leonard JM
    Salud Publica Mex; 1971; 13(3):313-7. PubMed ID: 5164661
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ; Robertson PW; Whybin LR
    Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Health and economic benefits of mandatory regular vaccination in Slovakia. IV. Measles, rubella and mumps].
    Hudecková H; Straka S; Avdicová M; Rusnáková S
    Epidemiol Mikrobiol Imunol; 2001 Feb; 50(1):31-5. PubMed ID: 11233671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 29. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA.
    Groves FD; Gridley G; Wacholder S; Shu XO; Robison LL; Neglia JP; Linet MS
    Br J Cancer; 1999 Sep; 81(1):175-8. PubMed ID: 10487630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Are measles and mumps vaccinations worth while in Switzerland?].
    Just M
    Schweiz Med Wochenschr; 1978 Nov; 108(45):1763-8. PubMed ID: 100878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccinations and risk of central nervous system demyelinating diseases in adults.
    DeStefano F; Verstraeten T; Jackson LA; Okoro CA; Benson P; Black SB; Shinefield HR; Mullooly JP; Likosky W; Chen RT;
    Arch Neurol; 2003 Apr; 60(4):504-9. PubMed ID: 12707063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The measles-mumps-rubella vaccination program in Finland.
    Lerman SJ
    N Engl J Med; 1995 Apr; 332(16):1103. PubMed ID: 7898541
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-benefit analysis in measles and mumps vaccinations].
    Wiedermann G; Ambrosch F
    Wien Med Wochenschr; 1978 Feb; 128(3):73-6. PubMed ID: 415440
    [No Abstract]   [Full Text] [Related]  

  • 38. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 39. [Modern trends in vaccination policy: evaluation of benefits, risks and cost (author's transl)].
    Wiedermann G
    Wien Klin Wochenschr; 1979 Mar; 91(5):143-50. PubMed ID: 106558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination against virus disease.
    Krugman S
    Maandschr Kindergeneeskd; 1968 Nov; 36(7):198-206. PubMed ID: 5715991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.